NASDAQ : FENC
Fennec Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 10.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 359.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 369.61M |
| Enterprise Value | 328.36M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 35.07M |
| Shares Outstanding | 35.07M |
| Shares Change (YoY) | +16.69% |
| Shares Change (QoQ) | +2.48% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 26.66% |
| Float | 19.85M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 19.05 |
| PS Ratio | 6.17 |
| Forward PS | 4.24 |
| PB Ratio | 8.45 |
| P/TBV Ratio | 8.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 5.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.85 |
| Quick Ratio | 5.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.19 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -18.58% |
| Return on Assets (ROA) | -1.16% |
| Return on Invested Capital (ROIC) | -2.59% |
| Return on Capital Employed (ROCE) | -1.77% |
| Weighted Average Cost of Capital (WACC) | 11.01% |
| Revenue Per Employee | $1.69M |
| Profits Per Employee | -$92,857 |
| Employee Count | 35 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 1.62 |
Taxes
| Measure | Value |
|---|
| Income Tax | 148,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +28.54% |
| 50-Day Moving Average | 10.92 |
| 200-Day Moving Average | 9.22 |
| Relative Strength Index (RSI) | 49.96 |
| Average Volume (20 Days) | 126,700 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 487,514 |
| Short Previous Month | 513,287 |
| Short % of Shares Out | 1.39% |
| Short % of Float | 2.46% |
| Short Ratio (days to cover) | 3.54 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 59.22M |
| Gross Profit | 55.51M |
| Operating Income | -1.12M |
| Pretax Income | -3.10M |
| Net Income | -3.25M |
| EBITDA | -1.02M |
| EBIT | -1.12M |
| Loss Per Share | -$0.10 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 41.25M |
| Total Debt | n/a |
| Net Cash | 41.25M |
| Net Cash Per Share | $1.18 |
| Equity (Book Value) | 42.44M |
| Book Value Per Share | 1.21 |
| Working Capital | 60.11M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.04M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 102,667 |
| Net Borrowing | -19.48M |
| Free Cash Flow | -2.04M |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | 93.73% |
| Operating Margin | -1.90% |
| Pretax Margin | -5.24% |
| Profit Margin | -5.49% |
| EBITDA Margin | -1.72% |
| EBIT Margin | -1.90% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.69% |
| Shareholder Yield | -16.69% |
| Earnings Yield | -0.96% |
| FCF Yield | -0.56% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $17.20 |
| Price Target Difference | 63.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 45.99% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 5, 2014 |
| Split Type | Reverse |
| Split Ratio | 1:3 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2.16 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |